Phreesia, Inc. (NYSE:PHR) SVP Sells $532,605.71 in Stock

Phreesia, Inc. (NYSE:PHR) SVP Amy Beth Vanduyn sold 25,447 shares of Phreesia stock in a transaction dated Tuesday, December 3rd. The shares were sold at an average price of $20.93, for a total transaction of $532,605.71. Following the completion of the transaction, the senior vice president now directly owns 93,470 shares of the company’s stock, valued at $1,956,327.10. This trade represents a 21.40 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Phreesia Stock Down 0.0 %

NYSE PHR traded down $0.01 on Thursday, reaching $21.15. 287,619 shares of the stock traded hands, compared to its average volume of 444,533. Phreesia, Inc. has a 12 month low of $17.07 and a 12 month high of $29.16. The company has a debt-to-equity ratio of 0.03, a quick ratio of 1.77 and a current ratio of 1.77. The firm’s fifty day simple moving average is $20.32 and its 200 day simple moving average is $21.79.

Phreesia (NYSE:PHR) last released its earnings results on Wednesday, September 4th. The company reported ($0.31) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.37) by $0.06. Phreesia had a negative return on equity of 39.34% and a negative net margin of 25.73%. The firm had revenue of $102.12 million for the quarter, compared to analyst estimates of $101.76 million. On average, analysts predict that Phreesia, Inc. will post -1.23 EPS for the current fiscal year.

Hedge Funds Weigh In On Phreesia

Several large investors have recently made changes to their positions in PHR. Franklin Resources Inc. lifted its stake in Phreesia by 3.0% during the third quarter. Franklin Resources Inc. now owns 1,497,631 shares of the company’s stock valued at $31,495,000 after purchasing an additional 42,973 shares during the last quarter. Geode Capital Management LLC lifted its position in shares of Phreesia by 4.7% during the 3rd quarter. Geode Capital Management LLC now owns 1,245,797 shares of the company’s stock valued at $28,397,000 after acquiring an additional 55,934 shares during the last quarter. M&T Bank Corp boosted its stake in shares of Phreesia by 4.6% during the 3rd quarter. M&T Bank Corp now owns 35,127 shares of the company’s stock worth $801,000 after acquiring an additional 1,535 shares in the last quarter. Barclays PLC grew its holdings in shares of Phreesia by 83.6% in the 3rd quarter. Barclays PLC now owns 94,929 shares of the company’s stock worth $2,163,000 after acquiring an additional 43,225 shares during the last quarter. Finally, XTX Topco Ltd acquired a new stake in shares of Phreesia during the third quarter worth $247,000. Institutional investors own 92.10% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have commented on the company. Truist Financial lifted their target price on Phreesia from $29.00 to $31.00 and gave the company a “buy” rating in a research note on Friday, September 6th. Robert W. Baird upped their price objective on Phreesia from $31.00 to $34.00 and gave the stock an “outperform” rating in a research note on Friday, September 6th. JMP Securities reiterated a “market outperform” rating and issued a $30.00 target price on shares of Phreesia in a research note on Thursday, September 5th. Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $23.00 price objective on shares of Phreesia in a report on Friday, September 27th. Finally, JPMorgan Chase & Co. lifted their price objective on shares of Phreesia from $27.00 to $28.00 and gave the company an “overweight” rating in a research report on Monday, September 9th. One research analyst has rated the stock with a hold rating and eleven have assigned a buy rating to the company. According to MarketBeat.com, Phreesia presently has an average rating of “Moderate Buy” and a consensus price target of $29.42.

Phreesia Company Profile

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.